3-Cyclopropoxy-5-methylpyridine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Cyclopropoxy-5-methylpyridine
• 英文别名: 3-cyclopropyloxy-5-methylpyridine
• 化学式: C₉H₁₁NO
• 分子量: 149.19
• InChiKey: JGZSZIKGAOPPQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Fused Aminodihydrothiazine Derivatives
  申请人：Dimopoulos Paschalis

  公开号：US20140011802A1

  公开（公告）日：2014-01-09

  The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C 1-6 alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, —CN, C 1-6 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C-6 alkoxy, C 3-6 cycloalkoxy and pyrazine, where C 1-6 alkyl and C 1-6 alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease 1 caused by Aβ and typified by Alzheimer-type dementia.

  本发明涉及一种公式（I）的融合氨基二氢噻唑衍生物：其中R是氢或C1-6烷基，可选地被一个至五个卤素原子取代；n是0、1、2或3；Ar是苯基或含1、2或3个N原子的5或6元杂芳族基团，其中Ar可选地被一个至三个选自卤素、羟基、—CN、C1-6烷基、C2-3烯基、C2-3炔基、C-6烷氧基、C3-6环烷氧基和吡嗪的取代基取代，其中C1-6烷基和C1-6烷氧基可选地被一个至三个卤素原子取代；以及药用可接受的盐；该化合物具有Aβ生成抑制效果或BACE1抑制效果，并且可用作预防或治疗由Aβ引起的神经退行性疾病1的预防或治疗剂，该疾病以阿尔茨海默症型痴呆为典型。
• US8822455B2
  申请人：——

  公开号：US8822455B2

  公开（公告）日：2014-09-02
• [EN] NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE DIACYLGLYCÉRIDE O-ACYLTRANSFÉRASE 2
  申请人：MERCK SHARP & DOHME

  公开号：WO2021236401A1

  公开（公告）日：2021-11-25

  Invented are compounds of formula I and the pharmaceutically acceptable salts thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.